KR102253721B1 - 벤조티오펜 화합물 - Google Patents

벤조티오펜 화합물 Download PDF

Info

Publication number
KR102253721B1
KR102253721B1 KR1020157036601A KR20157036601A KR102253721B1 KR 102253721 B1 KR102253721 B1 KR 102253721B1 KR 1020157036601 A KR1020157036601 A KR 1020157036601A KR 20157036601 A KR20157036601 A KR 20157036601A KR 102253721 B1 KR102253721 B1 KR 102253721B1
Authority
KR
South Korea
Prior art keywords
pain
compound
pharmaceutically acceptable
methyl
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157036601A
Other languages
English (en)
Korean (ko)
Other versions
KR20160015281A (ko
Inventor
츠카사 이시하라
가즈히로 이케가이
이쿠미 구리와키
히로유키 히사미치
노부아키 다케시타
류이치 다케자와
Original Assignee
아스테라스 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스테라스 세이야쿠 가부시키가이샤 filed Critical 아스테라스 세이야쿠 가부시키가이샤
Publication of KR20160015281A publication Critical patent/KR20160015281A/ko
Application granted granted Critical
Publication of KR102253721B1 publication Critical patent/KR102253721B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020157036601A 2013-06-06 2014-06-06 벤조티오펜 화합물 Expired - Fee Related KR102253721B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013119416 2013-06-06
JPJP-P-2013-119416 2013-06-06
PCT/JP2014/065141 WO2014196644A1 (ja) 2013-06-06 2014-06-06 ベンゾチオフェン化合物

Publications (2)

Publication Number Publication Date
KR20160015281A KR20160015281A (ko) 2016-02-12
KR102253721B1 true KR102253721B1 (ko) 2021-05-18

Family

ID=52005968

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157036601A Expired - Fee Related KR102253721B1 (ko) 2013-06-06 2014-06-06 벤조티오펜 화합물

Country Status (32)

Country Link
US (2) US8981119B2 (https=)
EP (1) EP3006443B1 (https=)
JP (1) JP6314978B2 (https=)
KR (1) KR102253721B1 (https=)
CN (1) CN105263926B (https=)
AR (1) AR096544A1 (https=)
AU (1) AU2014275768B2 (https=)
BR (1) BR112015030533B1 (https=)
CA (1) CA2914606C (https=)
CY (1) CY1120341T1 (https=)
DK (1) DK3006443T3 (https=)
ES (1) ES2671818T3 (https=)
HR (1) HRP20180722T1 (https=)
HU (1) HUE038920T2 (https=)
IL (1) IL242800B (https=)
LT (1) LT3006443T (https=)
MX (1) MX2015016743A (https=)
MY (1) MY199155A (https=)
NO (1) NO3006443T3 (https=)
PH (1) PH12015502637B1 (https=)
PL (1) PL3006443T3 (https=)
PT (1) PT3006443T (https=)
RS (1) RS57250B1 (https=)
RU (1) RU2667507C2 (https=)
SG (1) SG11201509989VA (https=)
SI (1) SI3006443T1 (https=)
SM (1) SMT201800306T1 (https=)
TR (1) TR201808724T4 (https=)
TW (1) TWI624466B (https=)
UA (1) UA117484C2 (https=)
WO (1) WO2014196644A1 (https=)
ZA (1) ZA201508866B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4003357A1 (en) 2019-07-23 2022-06-01 Astellas Pharma Global Development, Inc. Methods of treating sleep disorders associated with pain

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004532188A (ja) 2001-02-06 2004-10-21 グラクソ　グループ　リミテッド 増強したカリウムチャネル活性に応答する疾患の治療のための二環式エステルまたはアミドの使用
JP2006522130A (ja) 2003-04-03 2006-09-28 メルク　エンド　カムパニー　インコーポレーテッド ナトリウムチャンネル遮断薬としてのビアリール置換ピラゾール

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614639A (en) * 1995-03-31 1997-03-25 Eli Lilly And Company Process for preparing 2-substituted benzo[b]thiophene compounds and intermediates thereof
WO2003005025A1 (en) * 2001-07-03 2003-01-16 Biovitrum Ab Methods for identifying compounds modulating the activity of ppar-gamma
RU2006104621A (ru) 2003-07-15 2006-08-27 Смитклайн Бичам Корпорейшн (US) Новые соединения
WO2008054435A2 (en) * 2006-01-09 2008-05-08 The Regents Of The University Of California Use of sk channel activators to prevent relapse/reinstatement of drugs of abuse
US8022209B2 (en) * 2007-09-12 2011-09-20 Janssen Pharmaceutica Nv Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor
CN102272152B (zh) * 2008-11-10 2014-05-28 贝林格尔.英格海姆国际有限公司 通过中电导钙激活钾通道调控细胞-细胞融合的组合物及方法
AR090037A1 (es) 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004532188A (ja) 2001-02-06 2004-10-21 グラクソ　グループ　リミテッド 増強したカリウムチャネル活性に応答する疾患の治療のための二環式エステルまたはアミドの使用
JP2006522130A (ja) 2003-04-03 2006-09-28 メルク　エンド　カムパニー　インコーポレーテッド ナトリウムチャンネル遮断薬としてのビアリール置換ピラゾール

Also Published As

Publication number Publication date
CN105263926B (zh) 2018-05-11
JP6314978B2 (ja) 2018-04-25
RU2667507C2 (ru) 2018-09-21
NO3006443T3 (https=) 2018-09-22
IL242800B (en) 2019-06-30
WO2014196644A1 (ja) 2014-12-11
UA117484C2 (uk) 2018-08-10
PH12015502637B1 (en) 2019-02-08
MY199155A (en) 2023-10-18
ES2671818T3 (es) 2018-06-08
RU2015152150A (ru) 2017-07-13
PL3006443T3 (pl) 2018-09-28
TWI624466B (zh) 2018-05-21
TR201808724T4 (tr) 2018-07-23
CA2914606A1 (en) 2014-12-11
CA2914606C (en) 2021-03-23
MX2015016743A (es) 2016-03-21
US20140364421A1 (en) 2014-12-11
ZA201508866B (en) 2017-11-29
TW201536775A (zh) 2015-10-01
SI3006443T1 (en) 2018-08-31
IL242800A0 (en) 2016-02-01
US20150133433A1 (en) 2015-05-14
JPWO2014196644A1 (ja) 2017-02-23
SG11201509989VA (en) 2016-01-28
LT3006443T (lt) 2018-07-10
EP3006443A1 (en) 2016-04-13
BR112015030533A2 (pt) 2020-10-20
HUE038920T2 (hu) 2018-12-28
DK3006443T3 (en) 2018-06-25
EP3006443B1 (en) 2018-04-25
CY1120341T1 (el) 2019-07-10
US8981119B2 (en) 2015-03-17
SMT201800306T1 (it) 2018-07-17
RS57250B1 (sr) 2018-07-31
EP3006443A4 (en) 2016-12-21
AR096544A1 (es) 2016-01-13
CN105263926A (zh) 2016-01-20
HRP20180722T1 (hr) 2018-06-15
BR112015030533B1 (pt) 2023-02-28
AU2014275768B2 (en) 2017-12-14
PT3006443T (pt) 2018-06-07
KR20160015281A (ko) 2016-02-12
HK1215570A1 (zh) 2016-09-02
AU2014275768A1 (en) 2015-12-17
US9399038B2 (en) 2016-07-26
PH12015502637A1 (en) 2016-03-07

Similar Documents

Publication Publication Date Title
CA2793856C (en) Tetrahydrobenzothiophene compound
KR20090114439A (ko) 아실구아니딘 유도체
KR20120083292A (ko) 글리신 화합물
CN112020494A (zh) 用作tlr2信号转导调节剂的化合物
CA2792918A1 (en) Benzazepine compound
WO2010090305A1 (ja) 置換アシルグアニジン誘導体
KR102253721B1 (ko) 벤조티오펜 화합물
WO2021228215A1 (zh) 可用作RORγ调节剂的联芳基类化合物
EP2935254A1 (en) Compounds of 2,3-dihydro-4h-1,3-benzoxazine-4-one, method for preparing them and pharmaceutical form comprising them
HK1215570B (en) Bensothiophene compound

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240514

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240514